Geron(US:GERN) Globenewswire·2025-03-18 17:13Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Geron Corporation securities between June 7, 2024, and February 25, 2025, alleging misleading statements regarding the company's revenue outlook and growth potential [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Geron Corporation made false and misleading statements about its projected revenue and growth, downplaying risks associated with seasonality and macroeconomic factors [5]. - It is alleged that Geron's reports on the launch success of Rytelo, a telomerase inhibitor, did not accurately reflect the challenges faced in the market, including competition and the need for ongoing monitoring [5]. - The lawsuit indicates that when the true situation became known, investors suffered damages due to the misleading information provided by Geron [5]. Group 2: Class Action Participation - Investors who purchased Geron securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must file their motion by May 12, 2025 [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].